New Orleans, LA – The National Institute of Neurological Disorders and Stroke of the National Institutes of Health (NIH) has awarded $ 1.9 million in small business technology transfer technology (STTR) to South Rampart Pharma. The New Orleans Life Science Company is developing a new class of non-opioid drugs to relieve pain and reduce fever discovered at LSU Health New Orleans, its formal collaborating research institution and licensed to it.
The grant will fund the preclinical development of a late-stage new analgesic / antipyretic, and will also support ongoing collaboration with the LSU Health New Orleans Neuroscience Center of Excellence on pain mechanisms. A paper describing a patented new drug was recently published in the European Journal of Medicinal Chemistry. “Safe treatment of acute and chronic pain is one of the most widespread and expensive public health problems in the world,” said Hernan Bazan, MD, DFSVS, FACS, CEO and co-founder of South Rampart Pharma and professor of surgery at Ochsner Clinic, who is chief donation researcher. “Current drugs are either addictive or overuse damage to the liver or kidneys.”
“This startup represents a clinical translation application of LSU Health New Orleans’ findings, and this grant funding will help us advance the development of one of our leading drugs that as a non-narcotic has no potential for abuse and no liver and kidney toxicity associated with over-the-counter analgesics. “, said Dr. sc. Nicolas Bazan, scientific co-founder of South Rampart Pharma and director of LSU Health New Orleans Neuroscience Center of Excellence.
According to the National Institute of Neurological Disorders and Stroke, the burden of pain in the United States is staggering. More than 100 million Americans have pain that lasts for weeks to years. The financial tax of this epidemic costs 560 to 635 billion dollars a year. Pain is ultimately a challenge for family, friends, and health care providers who must provide support to an individual suffering from the physical and emotional consequences of pain.
The NIH says Small Business Innovation and Research Programs (SBIRs) and STTR are an integral source of capital for early-stage U.S. small businesses that create innovative technologies to improve health. These programs help small businesses break into the federal area of research and development (R&D), create life-saving technologies, and drive economic growth. The NIH STTR program is similar to the NIH SBIR program, but requires small businesses to formally collaborate with a research institution in Phase I and Phase II. The NIH expedited process accelerates decisions on the allocation and funding of SBIR and STTR II applications. Stages for scientifically deserving projects that have great potential for commercialization. In the U.S., only 19 competitive grants for the rapid commercialization of the NIH STTR were awarded in 2019. There has been no grant of this kind to institutions in the state of Louisiana in the past decade. Dr. Robert Naismith, co-founder of the Geisinger Commonwealth School of Medicine, which founded several life science companies, said: “The discovery by South Rampart Pharma of a potentially safer new chemical entity for pain treatment could potentially be a major clinical advance. Basic science makes clear the unique mechanism of action , which is recognized for its critical NIH support and accelerated NINDS label. ”
“Both acute and chronic pain affect hundreds of millions of people worldwide. Current pain medications often have side effects that can be serious, especially in the elderly affected by chronic diseases. The development of new safe analgesics is a must especially for them. I am excited to learn about a new class non-opioid drugs developed by the SRP, which recently received support from the NIH, “said Prof. Dr. Pierluigi Nicotera and Director of the Founders of the German Center for Neurodegenerative Disease Disease (DZNE) in Bonn, Germany.
“Pain is a serious problem for many people around the world and the possibility of new, safe, effective and non-addictive treatment is of great importance,” said Dr. Marianne Schultzberg, professor of neurobiology at the Karolinska Institutet in Stockholm, Sweden.
About LSU Health New Orleans:
The New Orleans LSU Center for Health Sciences educates Louisiana health professionals. The main state health science university, LSU Health New Orleans, includes the Medical College with branch campuses in Baton Rouge and Lafayette, the only public dental school, the only public school of public health in Louisiana, and schools of related health professions, nursing, and graduate studies. The LSU Health College of New Orleans cares for patients in public and private hospitals and clinics throughout the region. In the forefront of bioscience research in a number of areas on the world stage, research firm LSU Health New Orleans is creating jobs and huge economic impact. LSU Health College of New Orleans has made life-saving discoveries and continues to work to prevent, improve treatment, or cure disease. To learn more, visit http://www.lsuhsc.edu, http://www.twitter.com/LSUHealthNO or http://www.facebook.com/LSUHSC.
About South Rampart Pharma (SRP):
SRP is committed to improving the lives of people suffering from acute, chronic or neuropathic pain with new non-opioid pain medications. Proprietary SRP compounds are effective in reducing pain and fever in preclinical trials without liver and kidney toxicity associated with current conventional over-the-counter analgesics. SRP collaborates with top medical chemists across the United States and Spain in clinical and academic research centers on the development of oral and intravenous formulations (http://southrampartpharma.com).
Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of the announcements published on EurekAlert! by contributing to institutions or using any information through the EurekAlert system.